Alder BioPharmaceuticals

Alder BioPharmaceuticals is a biopharmaceutical company that discovers, develops, and seeks to commercialize genetically engineered therapeutic antibodies. Its lead product candidate, eptinezumab, is being evaluated for migraine prevention. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy.

Employee Rating

4.1More
StateClosed
TypeSubsidiary
Parent CompanyLundbeck
HQBothell, WA, US
Founded2004
Websitealderbio.com
Cybersecurity ratingAMore
Alder BioPharmaceuticals was founded in 2004 and is headquartered in Bothell, WA, US

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Alder BioPharmaceuticals

John Latham

John Latham

Chief Scientific Officer
Larry Benedict

Larry Benedict

Vice President, Finance
Mark Litton

Mark Litton

Chief Business Officer and Treasurer
Paul Cleveland

Paul Cleveland

Interim President and Chief Executive Officer
Show more

Alder BioPharmaceuticals Office Locations

Alder BioPharmaceuticals has an office in Bothell
Bothell, WA, US (HQ)
11804 North Creek Pkwy
Show all (1)

Alder BioPharmaceuticals Financials and Metrics

Summary Metrics

Founding Date

2004

Total Funding

$355 m

Investors

In total, Alder BioPharmaceuticals had raised $355 m. Alder BioPharmaceuticals is a subsidiary of Lundbeck

Alder BioPharmaceuticals Revenue

Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

Cost of goods sold

113.0k

General and administrative expense

12.5m16.7m26.1m38.1m47.5m

R&D expense

33.4m69.6m132.8m252.9m239.1m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

113.0k

Cost of goods sold

113.0k683.0k

Gross profit

General and administrative expense

3.2m2.7m3.2m3.7m3.9m4.3m6.0m6.5m6.2m10.0m9.5m8.2m11.7m12.2m10.7m44.5m21.6m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

46.8m206.5m116.2m76.9m87.9m

Accounts Receivable

113.0k113.0k

Prepaid Expenses

11.0m7.4m

Inventories

28.2m936.0k
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

12.9m70.3m57.6m209.9m408.0m234.0m178.0m230.0m170.6m79.7m127.8m87.3m202.0m115.8m94.4m126.1m88.4m

Accounts Receivable

91.0k57.0k81.0k

Prepaid Expenses

1.3m4.1m7.1m11.3m13.7m13.6m16.6m15.8m23.7m19.8m21.2m17.6m7.3m7.6m6.6m3.8m11.0m

Inventories

936.0k936.0k936.0k936.0k936.0k
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

8.9m(85.5m)(156.3m)(288.9m)(296.4m)

Depreciation and Amortization

701.0k751.0k1.7m3.0m2.6m

Inventories

95.0k(936.0k)936.0k

Accounts Payable

(312.0k)2.8m5.5m(2.4m)1.3m
Quarterly
USDQ1, 2014

Financial Leverage

-0.1 x
Show all financial metrics

Alder BioPharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Alder BioPharmaceuticals Online and Social Media Presence

Embed Graph

Alder BioPharmaceuticals News and Updates

Thinking about buying stock in Aclaris Therapeutics, Alder Biopharmaceuticals, Capricor Therapeutics, Canopy Growth, or ConocoPhillips?

NEW YORK, Sept. 17, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACRS, ALDR, CAPR, CGC, and COP. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Alder BioPharmaceuticals stock rockets on heavy volume after $1.95 billion buyout deal

Shares of Alder BioPharmaceuticals Inc. blasted 83% higher on very heavy volume in premarket trading Monday, after the developer of migraine treatment eptinezumab agreed to be bought out by Denmark-based H. Lundbeck A/S in a deal valued at $1.95 billion. Trading volume was already more than 4.6 m…

Alder (ALDR) Alert: Johnson Fistel Investigates Proposed Sale of Alder BioPharmaceuticals, Inc.; Are Shareholders Getting a Fair Deal?

SAN DIEGO, Sept. 16, 2019 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR) ("Alder") breached their fiduciary duties in connection with the proposed sale of the...

Alder BioPharmaceuticals, Inc. Announces Closing of Public Offering and Private Placement of Common Stock and Exercise in Full of Option to Purchase Additional Shares

BOTHELL, Wash., March 04, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, announced today the closing of its previously announced underwritten public offering of 13…

Alder BioPharmaceuticals, Inc. Prices Public Offering of Common Stock

BOTHELL, Wash., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, announced today the pricing of an underwritten public offering of 11,304,348 shares of its …

Alder BioPharmaceuticals Blogs

Fundamental Change Company Notice

ALDER BIOPHARMACEUTICALS, INC. FUNDAMENTAL CHANGE COMPANY NOTICE AND OFFER TO REPURCHASE TO THE HOLDERS OF ALDER BIOPHARMACEUTICALS, INC. 2.50% Convertible Senior Notes due 2025 (CUSIP NO. 014339AA3) THE OFFER TO REPURCHASE WILL EXPIRE AT 5:00 P.M., NEW YORK CITY TIME, ON December 11, 2019, UNLESS

Lundbeck and Alder BioPharmaceuticals announce updated information in the tender offer materials filed with SEC

Updated tender offer materials provide additional summary information regarding existing Lundbeck offer terms, including existing CVR terms, and additional information regarding existing Alder director and officer share ownership   Offer terms remain unchanged from commencement, with Lundbeck

Alder BioPharmaceuticals® Announces First-in-Human Dosing in Phase 1 ALD1910 Study for Preventive Treatment of Migraine

ALD1910 is Alder’s first clinical candidate designed to inhibit pituitary adenylate cyclase-activating polypeptide (PACAP), a novel target in treating migraine   BOTHELL, Wash. , Oct. 10, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on

Alder BioPharmaceuticals® to Present at Two Upcoming September Investor Conferences

BOTHELL, Wash. , Aug. 28, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that members of the management team will provide a business overview and

Alder BioPharmaceuticals® Reports Second Quarter 2019 Financial and Operating Results

Data presented at American Academy of Neurology and American Headache Society Annual Meetings continue to support eptinezumab’s differentiated clinical profile and impact on quality of life measures   Core commercial leadership team secured, including field payer team, in anticipation of expected

Alder BioPharmaceuticals® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Alder BioPharmaceuticals® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Content Import Fri, 08/02/2019 - 16:01 Alder BioPharmaceuticals® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 2, 2019 at 4:01 PM EDT This release …
Show more

Alder BioPharmaceuticals Frequently Asked Questions

  • When was Alder BioPharmaceuticals founded?

    Alder BioPharmaceuticals was founded in 2004.

  • Who are Alder BioPharmaceuticals key executives?

    Alder BioPharmaceuticals's key executives are John Latham, Larry Benedict and Mark Litton.

  • How many employees does Alder BioPharmaceuticals have?

    Alder BioPharmaceuticals has 202 employees.

  • Who are Alder BioPharmaceuticals competitors?

    Competitors of Alder BioPharmaceuticals include Orimed Pharma, Bencard Allergie and Chiesi Pharmaceutical.

  • Where is Alder BioPharmaceuticals headquarters?

    Alder BioPharmaceuticals headquarters is located at 11804 North Creek Pkwy, Bothell.

  • Where are Alder BioPharmaceuticals offices?

    Alder BioPharmaceuticals has an office in Bothell.

  • How many offices does Alder BioPharmaceuticals have?

    Alder BioPharmaceuticals has 1 office.